DAVENPORT & Co LLC lowered its stake in Sanofi SA (NYSE:SNY) by 2.1% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 22,859 shares of the company’s stock after selling 496 shares during the quarter. DAVENPORT & Co LLC’s holdings in Sanofi were worth $1,167,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Fisher Asset Management LLC increased its stake in shares of Sanofi by 0.7% in the 1st quarter. Fisher Asset Management LLC now owns 17,662,027 shares of the company’s stock valued at $772,184,000 after acquiring an additional 114,682 shares in the last quarter. BlackRock Inc. grew its position in Sanofi by 53.4% in the 1st quarter. BlackRock Inc. now owns 13,332,846 shares of the company’s stock valued at $582,911,000 after purchasing an additional 4,639,131 shares during the period. Morgan Stanley grew its position in Sanofi by 9.8% in the 1st quarter. Morgan Stanley now owns 5,142,760 shares of the company’s stock valued at $224,842,000 after purchasing an additional 460,930 shares during the period. Parametric Portfolio Associates LLC grew its position in Sanofi by 8.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 2,416,249 shares of the company’s stock valued at $105,638,000 after purchasing an additional 186,955 shares during the period. Finally, JPMorgan Chase & Co. grew its position in Sanofi by 2,013.4% in the 1st quarter. JPMorgan Chase & Co. now owns 1,957,992 shares of the company’s stock valued at $85,602,000 after purchasing an additional 1,865,346 shares during the period. Institutional investors own 7.04% of the company’s stock.

SNY has been the subject of several research reports. Barclays reissued an “equal weight” rating on shares of Sanofi in a research report on Tuesday, April 28th. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a research report on Tuesday, June 9th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Sanofi in a research report on Friday. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research report on Monday, May 18th. Finally, UBS Group reissued a “buy” rating on shares of Sanofi in a research report on Tuesday, May 26th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Sanofi presently has an average rating of “Buy” and a consensus target price of $54.00.

In other Sanofi news, major shareholder Sanofi sold 120,234 shares of Sanofi stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $597.48, for a total transaction of $71,837,410.32. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.00% of the stock is owned by insiders.

SNY opened at $52.45 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market capitalization of $131.34 billion, a price-to-earnings ratio of 16.76, a P/E/G ratio of 2.41 and a beta of 0.67. The firm’s fifty day moving average price is $51.68 and its two-hundred day moving average price is $48.67. Sanofi SA has a 1 year low of $37.62 and a 1 year high of $55.00.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Featured Article: How can investors invest in the Euro STOXX 50 Index?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.